These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23859002)

  • 1. Optimality of a time-dependent treatment profile during an epidemic.
    Jaberi-Douraki M; Moghadas SM
    J Biol Dyn; 2013; 7(1):133-47. PubMed ID: 23859002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can treatment increase the epidemic size?
    Xiao Y; Brauer F; Moghadas SM
    J Math Biol; 2016 Jan; 72(1-2):343-61. PubMed ID: 25925242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Choice of Antiviral Allocation Scheme for Pandemic Influenza Depends on Strain Transmissibility, Delivery Delay and Stockpile Size.
    Lydeamore M; Bean N; Black AJ; Ross JV
    Bull Math Biol; 2016 Feb; 78(2):293-321. PubMed ID: 26846916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of emerging antiviral drug resistance on influenza containment and spread: influence of subclinical infection and strategic use of a stockpile containing one or two drugs.
    McCaw JM; Wood JG; McCaw CT; McVernon J
    PLoS One; 2008 Jun; 3(6):e2362. PubMed ID: 18523549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling the effects of drug resistant influenza virus in a pandemic.
    Brockmann SO; Schwehm M; Duerr HP; Witschi M; Koch D; Vidondo B; Eichner M
    Virol J; 2008 Oct; 5():133. PubMed ID: 18973656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.
    Wu JT; Leung GM; Lipsitch M; Cooper BS; Riley S
    PLoS Med; 2009 May; 6(5):e1000085. PubMed ID: 19440354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing treatment regimes to hinder antiviral resistance in influenza across time scales.
    Patterson-Lomba O; Althouse BM; Goerg GM; Hébert-Dufresne L
    PLoS One; 2013; 8(3):e59529. PubMed ID: 23555694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative evaluation of modelling strategies for the effect of treatment and host interactions on the spread of drug resistance.
    Alexander ME; Dietrich SM; Hua Y; Moghadas SM
    J Theor Biol; 2009 Jul; 259(2):253-63. PubMed ID: 19344730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of drug resistance in the population: influenza as a case study.
    Moghadas SM
    Proc Biol Sci; 2008 May; 275(1639):1163-9. PubMed ID: 18270154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of drug-resistant influenza virus: population dynamical considerations.
    Regoes RR; Bonhoeffer S
    Science; 2006 Apr; 312(5772):389-91. PubMed ID: 16627735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral resistance and the control of pandemic influenza.
    Lipsitch M; Cohen T; Murray M; Levin BR
    PLoS Med; 2007 Jan; 4(1):e15. PubMed ID: 17253900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use.
    Arino J; Bowman CS; Moghadas SM
    BMC Infect Dis; 2009 Jan; 9():8. PubMed ID: 19161634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of optimal antiviral stockpile for a novel influenza pandemic.
    Kim S; Bin Seo Y; Lee J; Kim YS; Jung E
    J Infect Public Health; 2022 Jul; 15(7):720-725. PubMed ID: 35667304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The global spread of drug-resistant influenza.
    Chao DL; Bloom JD; Kochin BF; Antia R; Longini IM
    J R Soc Interface; 2012 Apr; 9(69):648-56. PubMed ID: 21865253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling strategic use of the national antiviral stockpile during the CONTAIN and SUSTAIN phases of an Australian pandemic influenza response.
    McVernon J; McCaw JM; Nolan TM
    Aust N Z J Public Health; 2010 Apr; 34(2):113-9. PubMed ID: 23331352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of drug resistance during an influenza epidemic: insights from a mathematical model.
    Stilianakis NI; Perelson AS; Hayden FG
    J Infect Dis; 1998 Apr; 177(4):863-73. PubMed ID: 9534957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination antiviral therapy for influenza: predictions from modeling of human infections.
    Perelson AS; Rong L; Hayden FG
    J Infect Dis; 2012 Jun; 205(11):1642-5. PubMed ID: 22448006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral prophylaxis during pandemic influenza may increase drug resistance.
    Eichner M; Schwehm M; Duerr HP; Witschi M; Koch D; Brockmann SO; Vidondo B
    BMC Infect Dis; 2009 Jan; 9():4. PubMed ID: 19154598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanded table: Antiviral drugs for treatment and prophylaxis of seasonal influenza 2018-2019.
    Med Lett Drugs Ther; 2019 Jan; 61(1563):e11-e12. PubMed ID: 30681664
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiviral drugs for treatment and prophylaxis of seasonal influenza.
    Med Lett Drugs Ther; 2019 Jan; 61(1563):1-4. PubMed ID: 30681660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.